• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Protective effect of grape seed extract and orlistat co-treatment against stroke: Effect on oxidative stress and energy failure
Publication date: April 2021Source: Biomedicine & Pharmacotherapy, Volume 136Author(s): Safwen Kadri, Mohamed El Ayed, Amal Kadri, Ferid Limam, Ezzedine Aouani, Meherzia Mokni
Source: Biomedicine and Pharmacotherapy - January 22, 2021 Category: Drugs & Pharmacology Source Type: research

Protective effect of grape seed extract and orlistat co-treatment against stroke: Effect on oxidative stress and energy failure.
Abstract Ischemic stroke is a major health concern and a leading cause of mortality worldwide. Oxidative stress is an early event in the course of stroke inducing neuro-inflammation and cell death. Grape seed extract (GSE) is a natural phytochemical mixture exhibiting antioxidant, anti-inflammatory and neuroprotective properties. Orlistat (ORL) is an anti-obesity agent and a gastro-intestinal lipase inhibitor which showed recently beneficial effects on brain lipotoxicity. Recent studies reported the increase of lipase activity upon stroke which led us to investigate the neuroprotective effect of ORL on rat brain I...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - January 20, 2021 Category: Drugs & Pharmacology Authors: Kadri S, El Ayed M, Kadri A, Limam F, Aouani E, Mokni M Tags: Biomed Pharmacother Source Type: research

Cardiovascular effects of current and future anti-obesity drugs.
Abstract The prevalence of obesity increases and is associated with increases in co-morbidities e.g. type 2 diabetes, hyperlipidemia, hypertension, obstructive sleep apnea, heart disease, stroke, asthma, several forms of cancer, depression, and may result in reduction of expected remaining lifespan. We have reviewed the adverse effects on the cardiovascular system of anti-obesity drugs now retracted from the market as well as the cardiovascular profile of current drugs and potential pathways which are considered for treatment of obesity. Fenfluramine, and sibutramine were withdrawn due to increased cardiovascular ...
Source: Current Vascular Pharmacology - May 24, 2014 Category: Drugs & Pharmacology Authors: Comerma-Steffensen S, Grann M, Andersen CU, Rungby J, Simonsen U Tags: Curr Vasc Pharmacol Source Type: research